Nuvation Bio (NUVB) Competitors

Nuvation Bio logo
$3.91 +0.07 (+1.90%)
Closing price 03:59 PM Eastern
Extended Trading
$3.93 +0.01 (+0.36%)
As of 07:55 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

NUVB vs. GRAL, MIRM, LGND, KOD, and IMVT

Should you buy Nuvation Bio stock or one of its competitors? Nuvation Bio's main competitors and comparable companies include GRAIL (GRAL), Mirum Pharmaceuticals (MIRM), Ligand Pharmaceuticals (LGND), Kodiak Sciences (KOD), and Immunovant (IMVT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Nuvation Bio compare to GRAIL?

Nuvation Bio (NYSE:NUVB) and GRAIL (NASDAQ:GRAL) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their analyst recommendations, valuation, dividends, media sentiment, institutional ownership, profitability, earnings and risk.

Nuvation Bio has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market. Comparatively, GRAIL has a beta of 2.86, meaning that its share price is 186% more volatile than the broader market.

In the previous week, GRAIL had 5 more articles in the media than Nuvation Bio. MarketBeat recorded 9 mentions for GRAIL and 4 mentions for Nuvation Bio. GRAIL's average media sentiment score of 0.60 beat Nuvation Bio's score of 0.14 indicating that GRAIL is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nuvation Bio
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
GRAIL
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Nuvation Bio presently has a consensus price target of $12.89, suggesting a potential upside of 233.13%. GRAIL has a consensus price target of $128.80, suggesting a potential upside of 21.97%. Given Nuvation Bio's stronger consensus rating and higher possible upside, equities research analysts clearly believe Nuvation Bio is more favorable than GRAIL.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvation Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67
GRAIL
1 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.33

Nuvation Bio has higher earnings, but lower revenue than GRAIL. GRAIL is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation Bio$62.90M21.71-$204.63M-$0.40N/A
GRAIL$147.17M32.26-$408.35M-$9.50N/A

61.7% of Nuvation Bio shares are owned by institutional investors. 30.1% of Nuvation Bio shares are owned by company insiders. Comparatively, 1.8% of GRAIL shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Nuvation Bio has a net margin of -67.38% compared to GRAIL's net margin of -243.80%. GRAIL's return on equity of -16.13% beat Nuvation Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvation Bio-67.38% -45.69% -18.54%
GRAIL -243.80%-16.13%-14.38%

Summary

Nuvation Bio beats GRAIL on 9 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Mirum Pharmaceuticals?

Mirum Pharmaceuticals (NASDAQ:MIRM) and Nuvation Bio (NYSE:NUVB) are both healthcare companies, but which is the better stock? We will compare the two companies based on the strength of their profitability, institutional ownership, media sentiment, valuation, earnings, dividends, analyst recommendations and risk.

Mirum Pharmaceuticals currently has a consensus target price of $155.56, suggesting a potential upside of 69.87%. Nuvation Bio has a consensus target price of $12.89, suggesting a potential upside of 233.13%. Given Nuvation Bio's higher possible upside, analysts clearly believe Nuvation Bio is more favorable than Mirum Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Mirum Pharmaceuticals
1 Sell rating(s)
0 Hold rating(s)
13 Buy rating(s)
1 Strong Buy rating(s)
2.93
Nuvation Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67

Nuvation Bio has a net margin of -67.38% compared to Mirum Pharmaceuticals' net margin of -134.75%. Nuvation Bio's return on equity of -45.69% beat Mirum Pharmaceuticals' return on equity.

Company Net Margins Return on Equity Return on Assets
Mirum Pharmaceuticals-134.75% -97.25% -12.59%
Nuvation Bio -67.38%-45.69%-18.54%

Mirum Pharmaceuticals has a beta of 0.75, indicating that its stock price is 25% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.73, indicating that its stock price is 73% more volatile than the broader market.

Mirum Pharmaceuticals has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Mirum Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Mirum Pharmaceuticals$521.31M11.47-$23.36M-$15.47N/A
Nuvation Bio$62.90M21.71-$204.63M-$0.40N/A

In the previous week, Mirum Pharmaceuticals had 13 more articles in the media than Nuvation Bio. MarketBeat recorded 17 mentions for Mirum Pharmaceuticals and 4 mentions for Nuvation Bio. Mirum Pharmaceuticals' average media sentiment score of 0.74 beat Nuvation Bio's score of 0.14 indicating that Mirum Pharmaceuticals is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Mirum Pharmaceuticals
6 Very Positive mention(s)
2 Positive mention(s)
6 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nuvation Bio
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

61.7% of Nuvation Bio shares are owned by institutional investors. 8.3% of Mirum Pharmaceuticals shares are owned by insiders. Comparatively, 30.1% of Nuvation Bio shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Mirum Pharmaceuticals and Nuvation Bio tied by winning 8 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Ligand Pharmaceuticals?

Nuvation Bio (NYSE:NUVB) and Ligand Pharmaceuticals (NASDAQ:LGND) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Ligand Pharmaceuticals has higher revenue and earnings than Nuvation Bio. Nuvation Bio is trading at a lower price-to-earnings ratio than Ligand Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Nuvation Bio$62.90M21.71-$204.63M-$0.40N/A
Ligand Pharmaceuticals$268.09M22.51$124.45M$2.24134.69

Nuvation Bio presently has a consensus target price of $12.89, suggesting a potential upside of 233.13%. Ligand Pharmaceuticals has a consensus target price of $355.38, suggesting a potential upside of 17.79%. Given Nuvation Bio's higher probable upside, equities research analysts clearly believe Nuvation Bio is more favorable than Ligand Pharmaceuticals.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Nuvation Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67
Ligand Pharmaceuticals
0 Sell rating(s)
1 Hold rating(s)
8 Buy rating(s)
0 Strong Buy rating(s)
2.89

Ligand Pharmaceuticals has a net margin of 20.27% compared to Nuvation Bio's net margin of -67.38%. Ligand Pharmaceuticals' return on equity of 5.22% beat Nuvation Bio's return on equity.

Company Net Margins Return on Equity Return on Assets
Nuvation Bio-67.38% -45.69% -18.54%
Ligand Pharmaceuticals 20.27%5.22%2.74%

In the previous week, Ligand Pharmaceuticals had 14 more articles in the media than Nuvation Bio. MarketBeat recorded 18 mentions for Ligand Pharmaceuticals and 4 mentions for Nuvation Bio. Ligand Pharmaceuticals' average media sentiment score of 0.80 beat Nuvation Bio's score of 0.14 indicating that Ligand Pharmaceuticals is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Nuvation Bio
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Ligand Pharmaceuticals
8 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Nuvation Bio has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market. Comparatively, Ligand Pharmaceuticals has a beta of 1.16, meaning that its share price is 16% more volatile than the broader market.

61.7% of Nuvation Bio shares are held by institutional investors. Comparatively, 91.3% of Ligand Pharmaceuticals shares are held by institutional investors. 30.1% of Nuvation Bio shares are held by insiders. Comparatively, 5.6% of Ligand Pharmaceuticals shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Summary

Ligand Pharmaceuticals beats Nuvation Bio on 12 of the 16 factors compared between the two stocks.

How does Nuvation Bio compare to Kodiak Sciences?

Kodiak Sciences (NASDAQ:KOD) and Nuvation Bio (NYSE:NUVB) are both healthcare companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, earnings, risk, analyst recommendations and media sentiment.

Kodiak Sciences currently has a consensus price target of $109.00, indicating a potential upside of 8.21%. Nuvation Bio has a consensus price target of $12.89, indicating a potential upside of 233.13%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Kodiak Sciences.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Kodiak Sciences
1 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.63
Nuvation Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67

89.1% of Kodiak Sciences shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 44.4% of Kodiak Sciences shares are held by company insiders. Comparatively, 30.1% of Nuvation Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Kodiak Sciences has a net margin of 0.00% compared to Nuvation Bio's net margin of -67.38%. Nuvation Bio's return on equity of -45.69% beat Kodiak Sciences' return on equity.

Company Net Margins Return on Equity Return on Assets
Kodiak SciencesN/A -223.93% -80.96%
Nuvation Bio -67.38%-45.69%-18.54%

In the previous week, Kodiak Sciences had 8 more articles in the media than Nuvation Bio. MarketBeat recorded 12 mentions for Kodiak Sciences and 4 mentions for Nuvation Bio. Kodiak Sciences' average media sentiment score of 0.57 beat Nuvation Bio's score of 0.14 indicating that Kodiak Sciences is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Kodiak Sciences
1 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nuvation Bio
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Nuvation Bio has higher revenue and earnings than Kodiak Sciences. Kodiak Sciences is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Kodiak SciencesN/AN/A-$229.97M-$4.08N/A
Nuvation Bio$62.90M21.71-$204.63M-$0.40N/A

Kodiak Sciences has a beta of 2.02, suggesting that its stock price is 102% more volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

Summary

Nuvation Bio beats Kodiak Sciences on 9 of the 15 factors compared between the two stocks.

How does Nuvation Bio compare to Immunovant?

Immunovant (NASDAQ:IMVT) and Nuvation Bio (NYSE:NUVB) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, earnings, institutional ownership, media sentiment and dividends.

47.1% of Immunovant shares are held by institutional investors. Comparatively, 61.7% of Nuvation Bio shares are held by institutional investors. 1.9% of Immunovant shares are held by insiders. Comparatively, 30.1% of Nuvation Bio shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Immunovant currently has a consensus target price of $44.60, indicating a potential upside of 34.01%. Nuvation Bio has a consensus target price of $12.89, indicating a potential upside of 233.13%. Given Nuvation Bio's stronger consensus rating and higher probable upside, analysts plainly believe Nuvation Bio is more favorable than Immunovant.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Immunovant
1 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.62
Nuvation Bio
1 Sell rating(s)
2 Hold rating(s)
9 Buy rating(s)
0 Strong Buy rating(s)
2.67

Immunovant has a beta of 0.95, indicating that its share price is 5% less volatile than the broader market. Comparatively, Nuvation Bio has a beta of 1.73, indicating that its share price is 73% more volatile than the broader market.

Nuvation Bio has higher revenue and earnings than Immunovant. Immunovant is trading at a lower price-to-earnings ratio than Nuvation Bio, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
ImmunovantN/AN/A-$505.61M-$2.56N/A
Nuvation Bio$62.90M21.71-$204.63M-$0.40N/A

In the previous week, Immunovant had 7 more articles in the media than Nuvation Bio. MarketBeat recorded 11 mentions for Immunovant and 4 mentions for Nuvation Bio. Immunovant's average media sentiment score of 0.66 beat Nuvation Bio's score of 0.14 indicating that Immunovant is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Immunovant
4 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nuvation Bio
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Immunovant has a net margin of 0.00% compared to Nuvation Bio's net margin of -67.38%. Nuvation Bio's return on equity of -45.69% beat Immunovant's return on equity.

Company Net Margins Return on Equity Return on Assets
ImmunovantN/A -63.01% -56.19%
Nuvation Bio -67.38%-45.69%-18.54%

Summary

Nuvation Bio beats Immunovant on 11 of the 14 factors compared between the two stocks.

Get Nuvation Bio News Delivered to You Automatically

Sign up to receive the latest news and ratings for NUVB and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding NUVB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

NUVB vs. The Competition

MetricNuvation BioBiotechnology IndustryHealthcare SectorNYSE Exchange
Market Cap$1.36B$4.06B$7.82B$23.23B
Dividend YieldN/A3.63%2.47%3.82%
P/E Ratio-9.7827.4232.3224.33
Price / Sales21.9616.068.563.20
Price / CashN/A22.9521.0115.54
Price / Book6.024.184.463.65
Net Income-$204.63M-$24.15M$3.52B$1.07B
7 Day Performance-7.27%-7.25%-5.47%-3.74%
1 Month Performance-11.77%-5.98%-4.57%-2.47%
1 Year Performance-16.10%-7.72%-1.79%6.03%

Nuvation Bio Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NUVB
Nuvation Bio
2.8994 of 5 stars
$3.91
+1.9%
$12.89
+229.4%
-20.4%$1.36B$62.90MN/A310
GRAL
GRAIL
2.5017 of 5 stars
$128.08
+5.5%
$121.40
-5.2%
+32.6%$6.42B$147.17MN/A910
MIRM
Mirum Pharmaceuticals
2.7919 of 5 stars
$93.18
-0.6%
$154.94
+66.3%
+28.2%$6.33B$521.31MN/A433
LGND
Ligand Pharmaceuticals
3.7385 of 5 stars
$314.15
+2.6%
$354.75
+12.9%
+50.2%$6.32B$268.09M140.2547
KOD
Kodiak Sciences
2.6358 of 5 stars
$107.10
+7.9%
$104.71
-2.2%
+416.3%$6.19BN/AN/A124

Related Companies and Tools


This page (NYSE:NUVB) was last updated on 11/17/2026 by MarketBeat.com Staff.
From Our Partners